TABLE 1.

Anti-HIV-1 activity of NRTI, NNRTI, or the integrase inhibitor^a

Drug	Jurkat cells			MT-4 cells			MDM cells			CD4+ T cells
	EC50 (μM)		FC	EC50 (μM)		FC	EC50 (μM)		FC	EC50 (μM)		FC
	−Vpx	+Vpx		−Vpx	+Vpx		−Vpx	+Vpx		−Vpx	+Vpx
AZT	0.023	0.034	1	0.017	0.082	5	0.015	0.389	26	0.068	4.607	67
d4T	5.000	4.300	1	0.962	2.376	2	0.300	2.009	7	1.245	1/>5b	1/>4b
3TC	0.164	0.156	1	0.816	0.758	1	0.081	0.022	1	0.524	0.372	1
ddC	0.052	0.059	1	0.292	0.308	1	0.113	0.042	1	0.115	0.081	1
ABC	0.053	0.059	1	0.001	0.001	1	0.003	0.003	1	0.015	0.009	1
TFV	11.598	10.858	1	2.877	2.162	1	6.114	5.599	1	1.949	6.822	3
ddI	2.045	2.572	1	1.470	2.692	2	1.805	2.251	1	0.402	0.481	1
NVP	0.090	0.095	1	0.237	0.295	1	0.274	0.361	1	1.017	1.256	1
EFV	0.038	0.072	2	0.047	0.055	1	0.071	0.071	1	0.068	0.091	1
RAL	0.003	0.007	3	0.005	0.004	1	0.022	0.031	1	0.017	0.015	1

^aNRTI are AZT, d4T, 3TC, ddC, TFV, ddI, and ABC; NNRTI are NVP and EFV; the integrase inhibitor is RAL. EC₅₀ values were calculated in T cell lines negative or expressing low levels of SAMHD1 (Jurkat and MT4) and primary cells MDM and CD4⁺ T cells. EC₅₀, effective concentration required to block HIV-1 replication by 50%; FC, fold change or ratio of the EC₅₀ with Vpx (+) and the EC₅₀ without Vpx (−). Results are the means from at least two independent experiments done in triplicates.

^bEC₅₀ > 5 μM in 2/5 donors, which resulted in a fold change of <4.